YL-17231

DRUG2 trials

Sponsors

Shanghai YingLi Pharmaceutical Co. Ltd.

Conditions

Advanced Solid TumorAdvanced Solid Tumors

Phase 1

A Study of YL-17231 in Patients With Advanced Solid Tumors

Shanghai YingLi Pharmaceutical Co. Ltd.Advanced Solid Tumor

Start: 2023-09-28End: 2025-12-31Target: 80Updated: 2023-10-12

Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS

RecruitingNCT06096974

Shanghai YingLi Pharmaceutical Co. Ltd.Advanced Solid Tumors

Start: 2023-10-24End: 2026-04-30Target: 60Updated: 2025-04-09